BSE filing, NSE: NYLOFIL. Summary written from the filing by ALFA Finder's alert engine.
Bhudevi Infra Projects Ltd: key numbers
- Share price
- ₹65.67
- Market cap
- ₹30.14 Cr
- Revenue (annual)
- ₹2.88 Cr
- Net profit (annual)
- ₹0.12 Cr
- P/E (TTM)
- 74.5×Sector 34.0×
- Promoter holding
- 71.18%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bhudevi Infra Projects Ltd
All →Bhudevi Infra Projects Annual General Meeting
Bhudevi Infra Projects Ltd held its 34th Annual General Meeting on September 30, 2026, where shareholders deliberated on routine agenda items including an authorised capital increase.
Bhudevi Infra Projects Annual General Meeting
Bhudevi Infra Projects Limited has issued a notice for its upcoming Annual General Meeting scheduled for September 30, 2026, in Hyderabad.
Bhudevi Infra Projects Annual Report
Bhudevi Infra Projects Limited has submitted its Annual Report and notice for the 34th Annual General Meeting to be held on September 30, 2026.
Bhudevi Infra Projects Board Meeting Outcome
Bhudevi Infra Projects approved an increase in authorised share capital to Rs. 10 Crore and scheduled its 34th Annual General Meeting for September 30, 2026.
Bhudevi Infra Projects Capacity Expansion: ₹170 Cr Investment
Bhudevi Infra Projects has commenced development of its residential project, Bhudevi Aurum Phase-1, in Hyderabad. The project is expected to contribute ₹170 Crore in revenue over four years.
- Value
- ₹170.0 Cr
- Execution
- 4 years
Bhudevi Infra Projects Q1 FY27 Results: Net Loss of ₹0.4 Cr, Loss Narrows
Bhudevi Infra Projects Ltd reported a net loss of ₹0.4 Cr for Q1 FY27.
- Key figure
- Net loss ₹0.4 Cr
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.